id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-E-2095-0006,FDA,FDA-2022-E-2095,Letter to U.S. Patent and Trademark Office,Other,Letter(s),2025-01-27T05:00:00Z,2025,1,2025-01-27T05:00:00Z,,2025-01-27T17:10:23Z,,0,0,0900006486900718
FDA-2022-E-2095-0005,FDA,FDA-2022-E-2095,Letter from FDA CDER to U S Patent and Trademark Office,Other,Letter(s),2024-02-05T05:00:00Z,2024,2,2024-02-05T05:00:00Z,,2024-02-05T19:16:44Z,,0,0,09000064863e5aba
FDA-2022-E-2095-0004,FDA,FDA-2022-E-2095,Determination of Regulatory Review Period for Purposes of Patent Extension; WELIREG,Notice,Determinations,2023-12-11T05:00:00Z,2023,12,2023-12-11T05:00:00Z,2024-02-10T04:59:59Z,2023-12-11T14:17:00Z,2023-27044,0,0,0900006486320d30
FDA-2022-E-2095-0003,FDA,FDA-2022-E-2095,Letter to U S Patent and Trademark Office from FDA CDER,Other,Correspondence,2022-09-13T04:00:00Z,2022,9,2022-09-13T04:00:00Z,,2022-09-13T15:24:53Z,,0,0,09000064852f7ec7
FDA-2022-E-2095-0002,FDA,FDA-2022-E-2095,"Patent Extension Application from Merck Sharp & Dohme Corp. (on behalf of Peloton Therapeutics, Inc.)",Other,Letter(s),2022-08-31T04:00:00Z,2022,8,2022-08-31T04:00:00Z,,2022-08-31T20:08:25Z,,0,0,090000648529e3ba
FDA-2022-E-2095-0001,FDA,FDA-2022-E-2095,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2022-08-31T04:00:00Z,2022,8,2022-08-31T04:00:00Z,,2022-08-31T20:08:16Z,,0,0,090000648529e3b4